ObjectiveTo study the relationship between plasma cardiac troponin I (cTnI) and global registry of acute coronary events (GRACE) risk score in patients with acute non ST segment elevation myocardial infarction (NSTEMI),and to assess the value of low GRACE risk score combined with plasma cTnI concentration in predicting hospital cardiovascular events in NSTEMI patients. MethodA total of 168 patients with NSTEMI treated between January 2011 and December 2012 were included in this study. Their serum CTnI level was measured instantly and on the second day (within 24 hours) to get the peak value. GRACE risk score was calculated by computer rating software. According to the GRACE risk score,risk stratification was performed,and patients were divided into low-risk group (n=48),middle-risk group (n=75) and high-risk group (n=45). Routine treatment was carried out for the patients during hospitalization. ResultsThe serum cTnI peak value was higher in high-risk patients than that in low-risk patients and middle-risk patients (P<0.05). The cTnI peak value was significantly higher in the middle-risk patients than in the low-risk patients (P<0.05). The incidence of major adverse cardiovascular events (MACE) in low-risk patients with higher serum cTnI peak value was relatively higher. Age,hyperlipidemia,and serum cTnI were closely related to MACE (P<0.05). ConclusionsFor NSTEMI patients with a low GRACE score,the MACE rate increases with the increase of serum cTnI concentration. GRACE low score and cTnI concentration have a certain clinical value in assessing the risk of MACE in NSTEMI patients.
Cardiovascular disease is the number one cause of death worldwide. A large body of epidemiologic evidence suggests that regular physical activity (PA) and high levels of cardiorespiratory fitness can prevent the progression of atherosclerotic cardiovascular disease and reduce the incidence of cardiovascular events. "Physical activity, cardiorespiratory fitness, and cardiovascular health: a clinical practice statement of the ASPC" released in December, 2022 by the American Society for Preventive Cardiology (ASPC) and provided the most up-to-date guidance on the associations and mechanisms between PA and cardiorespiratory fitness, the development of exercise prescriptions, and exercise-associated cardiovascular risk. In this article, the main content of this guideline was interpreted, aiming to develop a more scientific exercise prescription for patients with cardiovascular disease.